The FDA said it found unacceptable levels of NDMA (N-Nitrosodimethylamine) in extended-release versions of the type 2 diabetes drug metformin.

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) called for new product information for hormone replacement therapy (HRT) to reflect the risk of breast cancer.

A California appeals court has ruled that hundreds of Risperdal-related cases against Johnson & Johnson and its subsidiaries may proceed, reversing a decision that had dismissed the pending cases.